LASA SUPERGENERICS LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 22.78 INR | +0.09% |
|
-1.17% | -23.97% |
| 05-30 | Lasa Supergenerics Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024 | CI |
| 04-26 | Lasa Supergenerics CFO Steps Down | MT |
| Sales 2022 | 1.37B 16.43M 1.3B | Sales 2023 | 1.3B 15.52M 1.22B | Capitalization | 929M 11.13M 878M |
|---|---|---|---|---|---|
| Net income 2022 | -53M -635K -50.08M | Net income 2023 | -386M -4.62M -365M | EV / Sales 2022 | 1.26 x |
| Net Debt 2022 | 29.79M 357K 28.15M | Net Debt 2023 | 196M 2.35M 185M | EV / Sales 2023 | 0.87 x |
| P/E ratio 2022 |
-31.7
x | P/E ratio 2023 |
-2.41
x | Employees | 89 |
| Yield 2022 |
0.6% | Yield 2023 |
-
| Free-Float | 35.97% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.09% | ||
| 1 week | -1.17% | ||
| Current month | -1.73% | ||
| 1 month | +7.10% | ||
| 3 months | +5.07% | ||
| 6 months | -20.15% | ||
| Current year | -23.97% |
1 week
21.35
23.39
1 month
19.0025.05
Current year
19.0040.95
1 year
19.0040.95
3 years
17.2588.65
5 years
9.48100.15
10 years
9.48214.90
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 43 | 10/03/16 | |
Sunil Sitale
ADM | Chief Administrative Officer | - | - |
| Compliance Officer | 37 | 20/03/23 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 43 | 10/03/16 | |
| Director/Board Member | 63 | 01/05/17 | |
| Director/Board Member | 35 | 01/05/17 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 02/07/24 | 22.78 | +0.09% | 1 883 |
| 01/07/24 | 22.76 | -1.81% | 7,664 |
| 28/06/24 | 23.18 | +0.43% | 521 |
| 27/06/24 | 23.08 | -0.26% | 6,967 |
| 26/06/24 | 23.14 | +0.65% | 511 |
Delayed Quote Bombay S.E., July 02, 2024 at 11:00 am
More quotes
Lasa Supergenerics Limited is an India-based company, which is engaged in the business of manufacturing active pharmaceutical ingredients (API) bulk drugs products. The Company is engaged in the business of manufacturing, trading, producing, processing, preparing, treating chemicals, API, pharmaceuticals, drugs, and others. It is specialized in catalyst chemistry and manufactures anthelmintic/ veterinary API products with the production capabilities and product categories in India. The Company's products include API products, other API products, animal feed ingredients and reagents for therapeutic use. Its API products include Fenbendazole, Toldimphos sodium, Cyromazine, Albendazole, Riclabendazole, Rafoxanide, Ornidazole, 2,6-Diiodo-4-Nitrophenol, Ricobendazole, Oxfendazole, Closantel Base, Closantel sodium, Nitroxynil, Halquinol, and Oxyclozanide. The Company's manufacturing facility is located at Chiplun, Maharashtra.
Sector
Pharmaceuticals
Calendar
07/08/2024
- Q1 2025 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -11.43% | 78.75B | |
| -5.97% | 6.97B | |
| +22.12% | 3.7B | |
| -6.12% | 3.03B | |
| +12.67% | 1.66B | |
| -33.80% | 1.12B | |
| -36.68% | 1.07B | |
| -31.31% | 931M | |
| -16.35% | 891M |
- Stock Market
- Equities
- LASA Stock
- LASA Stock
